logomg.png
logomg.png
Open an Account
Open an Account

  • SENSEX

    {{sensexData[0].price}} (+{{sensexData[0].change}}%)

  • SENSEX

    {{sensexData[0].price}} ({{sensexData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} (+{{niftyData[0].change}}%)

  • NIFTY 50

    {{niftyData[0].open_price}} ({{niftyData[0].change}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} (+{{mcxData[2].PerChange}}%)

  • {{mcxData[2].symbol}}

    {{mcxData[2].price}} ({{mcxData[2].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} (+{{mcxData[0].PerChange}}%)

  • {{mcxData[0].symbol}}

    {{mcxData[0].price}} ({{mcxData[0].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} (+{{mcxData[1].PerChange}}%)

  • {{mcxData[1].symbol}}

    {{mcxData[1].price}} ({{mcxData[1].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} (+{{mcxData[3].PerChange}}%)

  • {{mcxData[3].symbol}}

    {{mcxData[3].price}} ({{mcxData[3].PerChange}}%)

Back
Lupin inks exclusive U.S. licensing deal with Valorum Biologics for biosimilar Armlupeg 
(14:45, 04 Dec 2025)
Under the terms of the agreement, Valorum will handle the commercialization and distribution of Armlupeg in the United States, while Lupin will be responsible for manufacturing and supplying the product. Lupin will receive an upfront license fee along with royalty payments on net sales.

Armlupeg (pegfilgrastim-unne) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy.

'We are pleased to collaborate with Valorum to expand access to affordable treatment options for patients undergoing chemotherapy. This partnership reflects our unwavering commitment to improving patient outcomes and aligns with our mission to make high-quality biosimilars more accessible. We look forward to strengthening our presence in the U.S. biosimilars market and building on our momentum as a global leader in developing and commercializing important biosimilar medicines,' said Spiro Gavaris, President ' U.S. Generics, Lupin.

Par S. Hyare, CEO of Valorum, said, 'We are excited to launch Armlupeg (pegfilgrastim-unne) in the U.S. Our team has a proven track record in specialty markets, and we expect to capture significant market share through our commercial expertise. Crucially, we also look forward to providing another option for healthcare providers and patients, increasing access to this important treatment in oncology supportive care.'

Valorum Biologics specializes in the U.S. commercialization of biosimilars, managing regulatory approval, product launch, and ongoing commercialization. The company focuses on optimizing patient access and delivering cost savings to the healthcare system.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Lupin reported a 73.33% surge in consolidated net profit to ₹ 1,477.92 crore in Q2 FY26 as against ₹ 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to ₹ 6,831.43 crore in the quarter ended 30 September 2025.

The counter rose 0.47% to ₹ 2,090.45 on the BSE.

Powered by Capital Market - Live News

No Details of this news available

Mandatory Dematerialization for Transfer of Securities, w.e.f 5th December 2018. Refer to SEBI notification number SEBI/LAD-NRO/GN/2018/24 dated June 08,2018.

Update/Link your Aadhaar Number with your Demat Account by Submitting a photocopy of Aadhaar card along with a request letter/Modification form.

Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment.

Prevent Unauthorized Transactions in your demat account. Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day....... Issued in the interest of investors.

Prevent unauthorized transactions in your trading account ->Update your mobile numbers/email IDs with your stock brokers. Receive information/alerts of your transactions directly from Exchange on your mobile/email at the end of the day.... Issued in the interest of investors.

Filing Complaints on SCORES - Easy & quick.
a. Register on SCORES portal,
b. Provide mandatory details for filing complaints on SCORES like name, PAN, address, mobile number, email ID.
c. Benefits:
   i. Effective communication
   ii. Speedy redressal of the grievances

Investor Awareness regarding the revised guidelines on margin collection

 

Dear Investor,

As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor.

https://www.bseipf.com/investors_education.html

We believe that an educated investor is a protected investor !!!

 

Risk Disclosure on Derivatives

  • out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:
SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

MAGNUM EQUITY BROKING LTD.

SEBI Registration No.: INZ000172031 NSE Member ID: 06529 | BSE Clearing No.:126 | CDSL SEBI Registration No. IN-DP-CDSL-201-2003
DP ID: 12029700 | CIN: U67120MH1996PLC103441

Investor Grievances: grievances@magnum.co.in

Copyright © 2018-2019 Magnum Equity Broking Ltd. All rights reserved

Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)